Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4NY58)

• Drug Name: SB-623 Drug Info
• Synonyms: (E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide

Indication

Disease Entry	ICD 11	Status	REF
Cerebrovascular ischaemia	8B1Z	Phase 2	[1]
Ischemic stroke	8B11.5Z	Phase 2	[2]
Stroke	8B20	Phase 2	[3]
Traumatic brain injury	NA07.Z	Phase 2	[3]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 6918876
  TTD Drug ID: DM4NY58

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[5]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[6]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[5]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[7]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[8]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[9]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[10]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[11]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[5]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT02448641) Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [5] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [6] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [9] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [10] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [11] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [12] 2011 Pipeline of 4SC AG.